Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
247.76
-8.76 (-3.41%)
Aug 11, 2026, 12:05 PM EDT - Market open
Jazz Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,620 | 1,392 | 2,413 | 1,506 | 881.48 | 591.45 |
Short-Term Investments | 580 | 1,050 | 580 | 120 | - | - |
Cash & Short-Term Investments | 2,200 | 2,442 | 2,993 | 1,626 | 881.48 | 591.45 |
Cash Growth | 31.73% | -18.41% | 84.03% | 84.50% | 49.04% | -59.33% |
Accounts Receivable | 880.9 | 830.75 | 716.77 | 705.79 | 651.49 | 563.36 |
Inventory | 443 | 416.96 | 480.45 | 597.04 | 714.06 | 1,073 |
Other Current Assets | 444.5 | 476.44 | 438.95 | 506.29 | 359.1 | 383.81 |
Total Current Assets | 3,968 | 4,166 | 4,629 | 3,435 | 2,606 | 2,611 |
Net Property, Plant & Equipment | 264.1 | 258.74 | 227 | 234.99 | 301.38 | 343.42 |
Other Intangible Assets | 4,030 | 4,430 | 4,756 | 5,418 | 5,794 | 7,152 |
Goodwill | 1,800 | 1,829 | 1,716 | 1,753 | 1,693 | 1,828 |
Other Long-Term Assets | 1,019 | 975.71 | 684.22 | 551.78 | 440.64 | 363.95 |
Total Assets | 11,081 | 11,659 | 12,012 | 11,393 | 10,835 | 12,299 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 128.5 | 122.06 | 77.87 | 102.75 | 90.76 | 100.3 |
Accrued Expenses | 1,030 | 1,034 | 910.95 | 793.91 | 803.26 | 666.3 |
Current Portion of Long-Term Debt | 1,016 | 1,030 | 31 | 604.95 | 31 | 31 |
Unearned Revenue | - | - | - | - | 0.46 | 2.09 |
Other Current Liabilities | 55.9 | 56.39 | 18.76 | 35.07 | 7.72 | 9.61 |
Total Current Liabilities | 2,231 | 2,243 | 1,039 | 1,537 | 933.19 | 809.3 |
Long-Term Debt | 3,335 | 4,328 | 6,078 | 5,108 | 5,693 | 6,019 |
Long-Term Leases | 43.6 | 50.89 | 38.94 | 59.23 | 71.84 | 87.2 |
Other Long-Term Liabilities | 669.8 | 718.99 | 763.35 | 952.46 | 1,051 | 1,418 |
Total Long-Term Liabilities | 4,048 | 5,098 | 6,880 | 6,120 | 6,816 | 7,524 |
Total Liabilities | 6,279 | 7,341 | 7,919 | 7,656 | 7,750 | 8,333 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.6 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
Additional Paid-in Capital | 4,332 | 4,240 | 3,914 | 3,700 | 3,477 | 3,535 |
Accumulated Other Comprehensive Income | -662.5 | -568.6 | -947.67 | -842.15 | -1,126 | -400.36 |
Retained Earnings | 1,132 | 646.18 | 1,127 | 878.66 | 733.59 | 830.23 |
Shareholders' Equity | 4,802 | 4,319 | 4,094 | 3,737 | 3,086 | 3,965 |
Total Liabilities & Equity | 11,081 | 11,659 | 12,012 | 11,393 | 10,835 | 12,299 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 4,395 | 5,409 | 6,148 | 5,772 | 5,796 | 6,137 |
Net Cash (Debt) | -2,195 | -2,967 | -3,155 | -4,146 | -4,915 | -5,546 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -33.70 | -48.66 | -47.79 | -57.53 | -78.59 | -92.90 |
Book Value | 4,802 | 4,319 | 4,094 | 3,737 | 3,086 | 3,965 |
Book Value Per Share | 73.72 | 70.82 | 62.02 | 51.86 | 49.34 | 66.43 |
Tangible Book Value | -1,028 | -1,940 | -2,378 | -3,434 | -4,401 | -5,015 |
Tangible Book Value Per Share | -15.78 | -31.82 | -36.03 | -47.65 | -70.38 | -84.01 |